Depression News and Research

Latest Depression News and Research

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy achieved significant improvements in both depression symptoms and in quality of life measurements.

9 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

Higher levels of income inequality in the U.S. lead to more deaths

A new study provides the best evidence to date that higher levels of income inequality in the United States actually lead to more deaths in the country over a period of years.

9 May 2012

Two studies suggest long-term value of Deplin in treating MDD

Two studies presented this week at the 164th Annual Meeting of the American Psychiatric Association suggest the long-term value of Deplin (L-methylfolate 15mg) in treating major depressive disorder (MDD) and describe subsets of patients who may benefit more robustly from this medical food.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

9 May 2012

Caring for carers

According to a new poll, there are hundreds of thousands of unpaid carers in Scotland who are suffering from mental health problems and struggling to keep their jobs.

8 May 2012

Ritalin use in ADHD rises four-fold over a decade

According to latest figures prescriptions for Ritalin for attention deficit hyperactivity disorder (ADHD) have quadrupled in a decade. This has raised concerns that it is being given to children at the expense of alternative treatments and without appreciation of long-term effects.

8 May 2012

New analysis on why some soldiers never seek PTSD care

U.S. Army researcher Maj. Gary H. Wynn, M.D., shared new analysis on why some Soldiers suffering from combat-related post-traumatic stress disorder (PTSD) never seek care or drop out of treatment early during a presentation today at the American Psychiatric Association's annual meeting. His presentation, "Epidemiology of Combat-Related PTSD in U.S. Service Members: Lessons Learned," also described the approaches the Army is using to address this issue and improve overall patient outcomes.

8 May 2012

Rare form of dementia eats away at personality and language

Michael French suffered from a rare form of dementia. It made him do unwise things like throwing away tax documents, getting a ticket for trying to pass an ambulance and buying stock in companies that were obviously in trouble. He seemed withdrawn and no longer spoke to his wife over dinner. He also lost his job at the consulting firm. This happened in 2006. His wife found he had changed suddenly from the smart, good-natured, hardworking man and was considering divorce when his ailment came into the picture.

8 May 2012

Cigna encourages new mothers to get screened for prenatal and postpartum depression

A mother's emotional health is as important as her physical health during pregnancy and after delivery. That's why, during May, Maternal Depression Awareness Month, Cigna (NYSE: CI) is encouraging soon-to-be and new mothers to get screened and understand the symptoms of prenatal and postpartum depression.

8 May 2012

DBS may offer hope for patients with mild Alzheimer's

A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson's disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Health Canada announces labelling update for Cipralex

Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).

7 May 2012

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Brain networks may avoid traffic jams by communicating on different frequencies

Brain networks may avoid traffic jams at their busiest intersections by communicating on different frequencies, researchers at Washington University School of Medicine in St. Louis, the University Medical Center at Hamburg-Eppendorf and the University of T-bingen have learned.

7 May 2012

AHA recognizes HHS’ Charla de Lupus program with HAVE

The American Hospital Association (AHA) has recognized Hospital for Special Surgery's Charla de Lupus (Lupus Chat) program with its Hospital Award for Volunteer Excellence.

5 May 2012

Researchers create new systematic assessment for malnutrition

A new systematic assessment of malnutrition, created by researchers at Penn State, will aid dietitians and other health care providers in diagnosis and treatment.

4 May 2012

Varenicline reduces alcohol intake among heavy-drinking smokers

The smoking cessation drug varenicline significantly reduced alcohol consumption in a group of heavy-drinking smokers, in a study carried out by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco.

4 May 2012

Repeated blows to the head associated with long term cognitive, pathologic changes

NFL great Junior Seau's apparent suicide might shock the sports world, but to neurosurgeons and neurologists accustomed to seeing an increase in the incidence of concussions, especially among football players, the news isn't as surprising.

3 May 2012

Depression News and Research

Latest Depression News and Research

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Higher levels of income inequality in the U.S. lead to more deaths

Two studies suggest long-term value of Deplin in treating MDD

eTNS therapy can impact symptoms in pharmacoresistant major depression

Caring for carers

Ritalin use in ADHD rises four-fold over a decade

New analysis on why some soldiers never seek PTSD care

Rare form of dementia eats away at personality and language

Cigna encourages new mothers to get screened for prenatal and postpartum depression

DBS may offer hope for patients with mild Alzheimer's

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Health Canada announces labelling update for Cipralex

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Brain networks may avoid traffic jams by communicating on different frequencies

AHA recognizes HHS’ Charla de Lupus program with HAVE

Researchers create new systematic assessment for malnutrition

Varenicline reduces alcohol intake among heavy-drinking smokers

Repeated blows to the head associated with long term cognitive, pathologic changes

Pharmaceutical Manufacturing - Industry Focus eBook eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Depression News and Research

Latest Depression News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in